TAXANES FOR OVARIAN AND BREAST CANCER

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer

Background

The aim of this systematic review was to bring together the most recent reliable data on the use of paclitaxel and docetaxel as first and second line treatment of advanced breast cancer; and, secondly, the use of paclitaxel as first line treatment of ovarian cancer. Adjuvant chemotherapy was not considered in this review.

Findings

This review is based on currently available evidence, which favours docetaxel in the second-line treatment of advanced breast cancer and paclitaxel in the first-line treatment of ovarian cancer. However, the evidence is not robust for any indication. There are several relevant trials in progress, which will need to be taken into consideration once they are suitably mature. Further recommendations for primary research are premature before the final results of ongoing research are published in full. Updating this systematic review is the most pertinent recommendation at this stage.

Conducted by: D Lister-Sharp1, MS McDonagh1, KS Khan1, J Kleijnen1

1. NHS Centre for Reviews and Dissemination

Further details

Project page on HTA Programme website

Related guidance

Commissioned to inform NICE Technology Appraisal 30: Taxanes for the treatment of breast cancer. London: National Institute for Clinical Excellence; 2001. NB: This guidance has been updated and replaced by CG81 Advanced breast cancer

Publications

Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the Taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess. 2000;4(17):1-113

Funding

Commissioned by the HTA Programme on behalf of NICE